Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,527 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Not applicable Interventional

Post-op Ketamine Study

NCT03865550
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Isotonic saline, Ketamine Injectable Solution
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
75 participants
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders

NCT02824627
View directory record Official record
Conditions
Mood Disorder, Disruptive Behavior Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Results available

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Clazakizumab, Physiologic saline solution
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

NCT03649724
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

NCT01659086
View directory record Official record
Conditions
Influenza
Interventions
Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Miami, Florida • Edison, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation

NCT07537894
View directory record Official record
Conditions
Abortion, Stillbirth, PTSD (Childbirth-Related), Grief (Traumatic Grief and Existential Grief)
Interventions
Dexmedetomidine (IV) 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

NCT01821118
View directory record Official record
Conditions
Cerebral Amyloid Angiopathy
Interventions
Ponezumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Charlestown, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 21, 2026, 5:32 PM EDT
Not listed Phase 2 Interventional

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

NCT05163080
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
SurVaxM
Biological
Lead sponsor
MimiVax, LLC
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

NCT04854486
View directory record Official record
Conditions
Covid19
Interventions
GSE and Xylitol, Control Placebo
Other · Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570
View directory record Official record
Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
RBX2660 (microbiota suspension), Placebo
Biological · Other
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Phase 4 Interventional

Ketamine in Colorectal Surgery

NCT02785003
View directory record Official record
Conditions
Acute Pain, Pain, Postoperative, Colorectal Surgery
Interventions
Placebo, Ketamine, Acetaminophen, Opioid, Alvimopan
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

NCT02985879
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 21, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Results available

Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure

NCT04410042
View directory record Official record
Conditions
Cancer of the Bone, Limb Salvage
Interventions
Tranexamic Acid, 0.9% sodium chloride
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupivacaine for Post-operative Pain in Mohs

NCT04362566
View directory record Official record
Conditions
Pain, Postoperative, Narcotic Use
Interventions
Bupivacaine, Placebo Saline
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

NCT01391182
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis
Interventions
EACA, Placebo arm
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 21, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

NCT07369024
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 5:32 PM EDT
Withdrawn Phase 2 Interventional

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT01504542
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
HS110 vaccine, Placebo
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

NCT01689441
View directory record Official record
Conditions
Severe Sepsis or Septic Shock
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 5:32 PM EDT